



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tasosartan

Cat. No.:	HY-A0250
CAS No.:	145733-36-4
Molecular Formula:	C ₂₃ H ₂₁ N ₇ O
Molecular Weight:	411.46
Target:	Angiotensin Receptor
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (303.80 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.4304 mL	12.1518 mL	24.3037 mL
		5 mM		0.4861 mL	2.4304 mL	4.8607 mL
		10 mM		0.2430 mL	1.2152 mL	2.4304 mL
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.06 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.
IC ₅₀ & Target	Angiotensin II (AngII) receptor ^[1]
In Vitro	Tasosartan is an orally active nonpeptide AngII antagonist that has demonstrates specific and selective AT1 receptor antagonistic activity in vitro. IC₅₀ for inhibition of specific binding of ¹²⁵I-AngII to rat adrenal membrane in the absence of proteins in binding buffer is 1.2±0.6 nM^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Administration of Tasosartan at doses of 1.0 and 3.0 mg/kg (iv) significantly ($p < 0.05$) attenuates the pressor response to angiotensin-II in rats^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Animal

Administration ^[2]

Rats^[2]

Pressor response to angiotensin-II administration in four groups of rats ($n = 3-5$ each, weighing 343 ± 8 g). Each rat is subjected to four separate bolus injections of angiotensin-II following the introduction of either the vehicle or graded doses of Tasosartan (0.3, 1.0, or 3.0 mg/kg, iv)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Maillard MP, et al. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54.

[2]. Elokda HM, et al. Novel human metabolites of the angiotensin-II antagonist Tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA